- Home
- IMTX vs STOK Comparison
IMTX vs STOK Comparison
Compare IMTX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- STOK
- Stock Information
- Founded
- IMTX N/A
- STOK 2014
- Country
- IMTX Germany
- STOK United States
- Employees
- IMTX N/A
- STOK N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- STOK Health Care
- Exchange
- IMTX Nasdaq
- STOK Nasdaq
- Market Cap
- IMTX 579.8M
- STOK 517.0M
- IPO Year
- IMTX N/A
- STOK 2019
- Fundamental
- Price
- IMTX $5.61
- STOK $11.58
- Analyst Decision
- IMTX Strong Buy
- STOK Strong Buy
- Analyst Count
- IMTX 4
- STOK 5
- Target Price
- IMTX $14.67
- STOK $24.50
- AVG Volume (30 Days)
- IMTX 754.4K
- STOK 534.4K
- Earning Date
- IMTX 08-12-2025
- STOK 08-06-2025
- Dividend Yield
- IMTX N/A
- STOK N/A
- EPS Growth
- IMTX N/A
- STOK N/A
- EPS
- IMTX N/A
- STOK 0.88
- Revenue
- IMTX $155,801,989.00
- STOK $190,908,000.00
- Revenue This Year
- IMTX N/A
- STOK $378.84
- Revenue Next Year
- IMTX $1.92
- STOK N/A
- P/E Ratio
- IMTX N/A
- STOK $13.21
- Revenue Growth
- IMTX 93.56
- STOK 2333.81
- 52 Week Low
- IMTX $3.30
- STOK $5.35
- 52 Week High
- IMTX $13.09
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- IMTX 51.00
- STOK 67.25
- Support Level
- IMTX $5.90
- STOK $11.43
- Resistance Level
- IMTX $6.38
- STOK $12.25
- Average True Range (ATR)
- IMTX 0.39
- STOK 0.51
- MACD
- IMTX -0.05
- STOK 0.02
- Stochastic Oscillator
- IMTX 16.30
- STOK 75.90
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.